Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + linperlisib + nab-paclitaxel in advanced NSCLC after prior immunotherapy progression
ChiCTR2400086436Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab, linperlisib and paclitaxel in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Primary endpoint: 6-month progression-free survival rate. Started Jul 2024; status: recruiting.
02
Drugs
adebrelimablinperlisibpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400086436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086436.